|
|
Article: Axikin and Proteros Enter into Fragment-Based Lead Discovery Collaboration.
- Article from:
- Business Wire
- Article date:
- March 30, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO, Calif. & MUNICH, Germany -- Axikin Pharmaceuticals ("Axikin"), San Diego, CA, U.S.A. and Proteros fragments ("Proteros"), Munich, Germany, a specialist structure-based lead discovery company, are pleased to announce today that they have entered into a significant research service collaboration to discover novel, customized lead compounds for the treatment of inflammatory diseases.
Under the terms of this collaboration, Proteros will provide multi-disciplinary research teams with the aim of generating multiple advanced lead series inhibiting a novel proprietary target protein.
In the initial stages of the programme Proteros shall solve the ...